<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161797</url>
  </required_header>
  <id_info>
    <org_study_id>KMC-ENDO-0801</org_study_id>
    <nct_id>NCT01161797</nct_id>
  </id_info>
  <brief_title>1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus</brief_title>
  <official_title>Correlation Between 1,5-anhydroglucitol and Postprandial Hyperglycemia by Continuous Glucose Monitoring System and Clinical Usefulness of 1,5-anhydroglucitol in Well-controlled Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the correlation between 1,5-Anhydroglucitol in patients&#xD;
      with HbA1C &lt;7%, and glycemic excursions as assessed by the continuous glucose monitoring&#xD;
      system compared to fructosamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1,5-Anhydroglucitol (AG) is a glucose analogue present in the plasma of healthy subjects.&#xD;
      Physiologically, the plasma levels of 1,5-AG are very stable and only a small quantity is&#xD;
      excreted in the urine. It is competitively reabsorbed with glucose in the renal tubules.&#xD;
      Therefore, in the hyperglycemic state where glycosuria is present, glucose competitively&#xD;
      inhibits renal tubular reabsorption of 1,5-AG and consequently the plasma 1,5-AG levels&#xD;
      decrease. When glycemia is normalized and glycosuria is resolved, 1,5-AG levels increase.&#xD;
&#xD;
      The usefulness of 1, 5-AG in reflecting glycemic excursions have been demonstrated in&#xD;
      moderately controlled patients to some extent, although some studies reveal controversial&#xD;
      results.&#xD;
&#xD;
      Therefore, the aim of this study was to evaluate the association of 1,5-AG and postprandial&#xD;
      hyperglycemia determined using the Continuous Glucose Monitoring System (CGMS) in DM patients&#xD;
      with HbA1C&lt;7% and evaluate the usefulness of 1,5-AG as a marker of glycemic control compared&#xD;
      to HbA1C and fructosamine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial hyperglycemia</measure>
    <time_frame>3days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose variability</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum (HbA1c, fructosamine, 1,5-anhydroglucitol)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Well-controlled patients with type 2 diabetes with HbA1c&lt;7%&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HbA1C &lt; 7%&#xD;
&#xD;
          -  HbA1c modification &lt;0.5% in the previous 3 months&#xD;
&#xD;
          -  no recent addition of oral hypoglycemic medications or change in insulin dose &gt;10%&#xD;
             previous 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  anemia (Hb &lt;10.0 g/dL)&#xD;
&#xD;
          -  liver disease (ALT &gt;2 UNL)&#xD;
&#xD;
          -  hypoalbuminemia (albumin &lt;3.5 g/dL)&#xD;
&#xD;
          -  serum creatinine &gt;2 mg/dL&#xD;
&#xD;
          -  acute or chronic renal tubulointerstitial disease&#xD;
&#xD;
          -  severe medical illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-taek Woo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>September 29, 2010</last_update_submitted>
  <last_update_submitted_qc>September 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jeong-taek Woo, MD, PhD</name_title>
    <organization>Kyunghee University Medical Center</organization>
  </responsible_party>
  <keyword>1,5-Anhydroglucitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

